Fiabilidad de la ecografía en la evaluación del grosor muscular en niños críticamente enfermos / Reliability of ultrasound in the assessment of muscle thickness in critically ill children

Introducción: La ecografía se ha utilizado para cuantificar y calificar la morfología muscular de niños críticamente enfermos, detectando posibles cambios en el grosor muscular. El objetivo del estudio fue evaluar la fiabilidad de la medición por ecografía del grosor muscular en niños críticamente enfermos, y comparar la evaluación de un examinador experto con la de examinadores con poca experiencia. Material y métodos: Estudio observacional transversal en la unidad de cuidados intensivos pediátricos de un hospital universitario de tercer nivel en Brasil. Se incluyeron pacientes entre un mes y 12 años, que recibieron ventilación mecánica invasiva durante un mínimo de 24h. Se obtuvieron imágenes ecográficas del bíceps braquial/braquial y cuádriceps femoral en evaluaciones realizadas por un ecografista experimentado y ecografistas inexpertos. La concordancia intra- e interevaluador se estableció mediante el coeficiente de correlación intraclase (CCI) y el análisis gráfico de Bland-Altman. Resultados: Se midió el grosor muscular en 10 niños con una edad media de 15,5 meses. El grosor medio de los músculos evaluados fue de 1,14 ±0,27cm para el bíceps braquial/braquial y de 1,85±0,61cm para el cuádriceps femoral. La fiabilidad intraevaluador e interevaluador fue muy buena (CCI>0,81) para todos los ecografistas. Las diferencias fueron pequeñas, sin detectarse en el análisis de los gráficos de Bland-Altman, y todas las mediciones estuvieron dentro de los límites de concordancia, excepto una medición de bíceps y cuádriceps. Conclusión: La ecografía se puede utilizar en niños en estado crítico para evaluar con precisión los cambios en el grosor muscular, incluso por diferentes evaluadores. Se necesitan más estudios para establecer un enfoque estandarizado en el uso de esta herramienta para la monitorización de la pérdida muscular con el fin de incorporar su uso en la práctica clínica. (AU)

Introduction: Ultrasound has been used to quantify and qualify muscle morphology in critically ill children and can detect changes in muscle thickness. The aim of this study was to assess the reliability of ultrasound measurement of muscle thickness in critically ill children and to compare the assessments made by an expert with those made by inexperienced sonographers. Material and methods: Cross-sectional observational study conducted in the paediatric intensive care unit of a tertiary care university hospital in Brazil. The sample included patients aged 1 month to 12 years who received invasive mechanical ventilation for at least 24hours. Ultrasound images of the biceps brachii/brachialis and quadriceps femoris were obtained by one experienced sonographer and several inexperienced sonographers. We assessed intrarater and inter-rater reliability by means of the intraclass correlation coefficient (ICC) and Bland-Altman plot analysis. Results: Muscle thickness was measured in 10 children with a mean age of 15.5 months. The mean thickness of the assessed muscles was 1.14cm for the biceps brachii/brachialis (standard deviation [SD]: 0.27) and 1.85cm for the quadriceps femoris (SD: 0.61). The intrarater and inter-rater reliability were good for all sonographers (ICC>0.81). The differences were small, there was no significant bias in the Bland-Altman plots and all measurements were within the limits of agreement, except for 1 measurement of biceps and quadriceps. Conclusion: Sonography can be used in critically ill children to accurately assess changes in muscle thickness, even by different evaluators. More studies are needed to establish a standardised approach to the use of ultrasound for monitoring muscle loss in order to incorporate it in clinical practice. (AU)

Identification of CD114 Membrane Receptors as a Molecular Target in Medulloblastomas.

Medulloblastomas are the most common solid tumors in children, accounting for 8-30% of pediatric brain cancers. It is a high-grade tumor with aggressive behavior and a typically b poor prognosis. Its treatment includes surgery, chemotherapy, and radiotherapy, and presents high morbidity. Significant clinical, genetic, and prognostic differences exist between its four molecular subgroups: WNT, SHH, Group 3, and Group 4. Many studies seek to develop new chemotherapeutic agents for medulloblastomas through the identification of genes whose expressions are new molecular targets for drugs, such as membrane receptors associated with cell replication. This study aimed to assess the association of CD114 expression with mortality in patients with medulloblastoma. Databases from the Medulloblastoma Advanced Genomics International Consortium (MAGIC) were analyzed, focusing on the expression of the CD114 membrane receptor in different molecular types and its possible association with mortality. Our findings showed different CD114 expressions between Group 3 and other molecular groups, as well as between the molecular subtypes SHH γ and Group 3 α and Group 3 ß. There was no statistically significant difference between the other groups and subtypes. Regarding mortality, this study did not find statistical significance in the association between low and high CD114 expressions and mortality. Medulloblastoma is a heterogeneous disease with many subtype variations of its genetic and intracellular signaling pathways. Similarly to this study, which could not demonstrate different CD114 membrane receptor expression patterns between groups, others who sought to associate CD114 expression with mortality in other types of cancer failed to establish a direct association. Since many indications point to the relation of this gene with cancer stem cells (CSCs), it may be part of a more extensive cellular signaling pathway with an eventual association with tumor recurrence. This study found no direct relationship between CD114 expression and mortality in patients with medulloblastoma. Further studies are needed on the intracellular signaling pathways associated with this receptor and its gene (the CSF3R).